Pregnancy
Meet the California start-up reimagining prenatal screening
Biotech start-up Juno Diagnostics is poised to support women through every step of the pregnancy journey
Born out of a need to address the problems within the US prenatal healthcare system, Juno Diagnostics is on a mission to shake up the landscape of traditional prenatal care. We speak to co-founder and chief medical officer, Dr Mathias Ehrich, and director of genetic counselling, Katie Sagaser, to find out more.
Tell us a bit more about the story behind Juno.
Mathias Ehrich: Our aim has always been to create equitable access to high-quality prenatal care. We want all women to have the opportunity to learn about their pregnancy and feel empowered to make informed decisions.
In launching the world’s first capillary-based cfDNA non-invasive prenatal screening test, we looked to create an affordable test that met our goals of accessibility and transparency.
So in 2011, the Juno co-founders and I were working together at a life sciences company to pioneer the development and commercialisation of the first cell-free DNA-based non-invasive prenatal screen (NIPS) in the United States.
There, we drove a lot of innovation in pregnancy care and prenatal care up until the company was acquired in 2016. At the time, only about 800,000 women had true access to NIPS.
So when we looked at the problem again, we found a couple of things in the market that were not working.
First of all, most NIPS tests were too expensive, and second of all, they were difficult to access. In almost 50 percent of all US counties, women don’t even have access to an OB/GYN, let alone a phlebotomy service.
So women really had a problem with getting access to NIPS technology.
That’s when we realised that we needed to develop something that we could send in the mail and that could be shipped in a box, in a cheaper and a lot more accessible way. We needed to meet women where they are.
Katie Sagaser: From my experience as a genetic counsellor, I was able to see the ways in which a new type of test is introduced, especially in the genetic testing world.
There’s a lot of ‘healthy fear’ at first, but sometimes that ends up paralysing patients in a way that if we, as folks in industry, don’t equip them with the right resources, it prevents them from being able to utilise technology that can be extremely empowering, in this case, for their pregnancy.
NIPS is not novel anymore. Yet, there are still OB-GYN providers out there who are reticent to incorporate it into their routine screening programmes for whatever reasons.
So one of the things that we have really wanted to do at Juno is work together with our providers, colleagues and partners, to try to equip them with the resources that they need to help their patients get the information that’s right for them and to ultimately, make an informed decision.
How does your approach help women access pre-natal screening tests at home?
KS: We’ve designed an extremely personalised approach because we really want to be meeting people right where they are.
At present, for the non-invasive prenatal screening test, there are two different pathways that people can follow.
They can either request the test themselves and a physician will review the order request and approve it, or their provider can order the test for them.
Once the order is placed, the patient is prompted to set up a Zoom call for a sample collection. This is going to be the same whether they’re doing the non-invasive prenatal screening test or the foetal gender test.
After the actual sample collection, patients are equipped with everything they need to return the kits. They just have to send them to the lab.
After we analyse the sample, they can access their results in their myJuno account.
What’s really unique is that our platform keeps them informed every step of the way, similar to how they might be used to tracking an order.

ME: We always wanted to empower women and encourage them to do things at their own pace. They have all the information they need on the platform and if something isn’t clear, they can get in touch with a genetic counsellor at any time of the process.
However, the platform is not a replacement for their OB-GYN provider. It’s something that’s intended to complement those services and make everybody’s life easier.
A lot of people were introduced to at-home testing during the pandemic. Do you think Covid has changed the way people view digital health?
KS: I think that prior to 2020, especially in the genetic counselling space, the whole concept of telemedicine was still intriguing. Covid has definitely changed that.
However, I think there are still challenges in the United States pertaining to our maternal health crisis and our OB-GYN access that telehealth on its own is not going to instantly fix.
ME: I think the pandemic did bring about a pretty big shift in the minds of the providers and they started to become more open to things like telehealth and taking care of patients remotely.
You’ve launched three products in 2022. What feedback have you received so far?
KS: The feedback has been exceptionally positive. I have been helping out with some of the Zoom calls on the collection side and people really appreciate the kind of support that we offer.
First of all, they like the fact that they’re talking with a real person in real time, but they also like that when they have questions, they don’t feel like a burden, and they can seek help and express their concerns.
Currently, the tests are only available in the US. Are you considering expanding your services globally?
ME: We’re extremely proud of all the work that we did in 2022. Yes, as we continue to grow, we’re considering expanding beyond the US when the time is right and in a way that is most appropriate.
It’s not Europe! I think Europe will be on our list at some point as well, but it is a little bit more difficult since most European countries have very particular healthcare systems to navigate. We promise it’s something exciting, though!
For more info, visit junodx.com.
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Fertility
Most NHS regions in England limit IVF to single cycle, research finds
Nearly 70 per cent of NHS regions in England fund only one IVF cycle for women under 40, breaking national guidelines, new research has found.
Twenty-nine of the 42 integrated care boards, which control local NHS budgets, now offer only one round of treatment, after four reduced access in the past year.
National Institute for Health and Care Excellence (Nice) guidelines recommend three full cycles for women under 40 who have been unable to conceive for two years.
Only two of England’s 42 integrated care boards have policies consistent with these guidelines, which they are not legally obliged to follow.
The research was conducted by the Progress Educational Trust, a fertility charity.
Sarah Norcross, the director of PET, said the impact was “devastating” for couples struggling with infertility.
She said: “Infertility is already incredibly stressful for people, and it puts them under even more pressure, because there is so much riding on whether that one NHS-funded cycle is going to work.
“And for some people, that will be their only chance, because private fertility treatment is so expensive.”
The data showed regional variations, with the whole of the north-west offering just one cycle.
“It’s a postcode lottery, and we’re seeing a race to the bottom,” said Norcross.
Of the 29 integrated care boards that offer a single cycle, 19 provide only a partial cycle, where not all viable embryos created are transferred.
There was just one recent example of improved services, from NHS South East London, which in July 2024 went from one partial to two full cycles.
The NHS estimates that about one in seven couples may have difficulty achieving a pregnancy. One cycle of IVF can cost from £5,000 at a private clinic.
Fertility rates in England and Wales have fallen since 2010 to 1.41 children per woman in 2024, the lowest on record and below the replacement level of 2.1 at which a population is stable without immigration.
Health minister Karin Smyth said in a written parliamentary answer last month that it was “unacceptable” that access to NHS-funded fertility services varied across the country.
Revised Nice fertility guidelines are due this spring, but Norcross said changing them seemed pointless.
She said: “Fertility treatment has always been a Cinderella service. It’s always been the one they’ve chosen to cut or to ignore.
“Nice has recommended three full NHS-funded cycles, for women under 40, for more than 20 years. This has never been implemented across England, unlike in Scotland.”
Norcross advocated centralised commissioning and replicating Scotland’s approach, which included financial modelling and a phased implementation starting with two cycles to avoid long waits, moving up to three once capacity was achieved.
“It is a tried and tested plan that England could follow,” Norcross added.
A Department of Health and Social Care spokesperson said: “We recognise access to fertility treatment varies across the country and we are working with the NHS to improve consistency.
“Nice provides clear clinical guidelines, and we expect integrated care boards to commission treatment in line with these.
“Updated Nice fertility guidelines are expected this spring and we will continue to support NHS England to make sure the guidance is fully considered in local commissioning decisions.”
An NHS England spokesperson said: “These clinical services are commissioned by integrated care boards for their area based on the needs of the local population and prioritisation of resources available.
“All ICBs have a responsibility to ensure services are provided fairly and are accessible by different population groups.”
Fertility
France urges 29-year-olds to start families now
France is urging 29-year-olds to have children as part of a 16-point plan to boost fertility and raise birth rates.
Health officials say the aim is to prevent men and women facing fertility problems later in life and thinking “if only I had known”.
The strategy comes as the country, like many western nations including the UK, faces tumbling birth rates.
The trend is creating concerns about how governments can fund pensions and healthcare for ageing populations with fewer younger working people paying taxes.
But policies to raise fertility rates globally have produced limited results, and critics of the scheme suggest better housing and maternity provision could be more effective.
The government will send out “targeted, balanced, and scientifically sound information” to young people on issues including sexual health and contraception.
The material “will also reiterate that fertility is a shared responsibility between women and men,” the country’s health ministry said.
The plan includes efforts to increase the number of egg-freezing centres from 40 to 70. The process involves extracting and storing a woman’s eggs for potential future use.
The country’s health system already provides free egg-freezing for people aged 29 to 37, a service that costs about £5,000 per round in the UK.
The country’s fertility rate of 1.56 children per woman is below the 2.1 needed to maintain a stable population.
However, it is higher than rates in China, Japan and South Korea, and the UK, where the latest figures show it dropped to a record low of 1.41 in England and Wales by 2024.
Professor François Gemenne, who specialises in sustainability and migration at HEC Paris Business School, told Sky News: “This is something that demographers had known for a long time, but the fact that there were more deaths than births in France last year created a shock effect.”
He said the country’s “demographic worry” is exacerbated by the design of its pensions system and its “obsession with immigration and the fear of being ‘replaced'”.
The plan also includes a new national communication campaign, a “My Fertility” website advising on the effects of smoking, weight and lifestyle, and school lessons for children about reproductive health.
The health ministry has acknowledged its maternal and infant mortality rates are higher than neighbouring countries and is beginning a review of perinatal care to address the “concerning” situation.
Channa Jayasena, professor in reproductive endocrinology at Imperial College London, told Sky News: “On the female side, societal changes leading to older age of motherhood are certainly important.
He said obesity was also a problem as it increased women’s risk of polycystic ovary syndrome and endometriosis.
Allan Pacey, professor of andrology (male reproductive health) at Manchester University, said for most people globally, deciding to have children was “down to [non-medical] factors such as better access to education, career opportunities, taxation, housing, mortgages, finance, etc.”
“Medicine can’t help with those things,” Pacey added.
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







Pingback: California biotech start-up shuts down commercial operations - FemTech World